Concepedia

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, Odoardo Maria Olimpieri, Fabrizio Pane, Alessandra Iurlo, Alessia Cirilli, Antonietta Colatrella, Lucia Gozzo, Sara Pugliese,

Annals of Hematology · 2021 · 18 citations · 9 references

DOI

Concepts

References

9

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, François Guilhot et al. · New England Journal of Medicine · 2017 · 1.3K citations · Full text

, , +12

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2016 · 946 citations · Full text

, , +12

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

Hannah Bower, Magnus Björkholm, Paul W. Dickman et al. · Journal of Clinical Oncology · 2016 · 886 citations · Full text

, , +14

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 850 citations · Full text

, , +11

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour et al. · Blood · 2012 · 338 citations · Full text

, , +5